PLx Pharma (PLXP) Stock Price, News & Analysis

Company Overview

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3,000 shs
• Average Volume: 12.96 million shs
• Market Capitalization: $603,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PLXP Stock Analysis - Frequently Asked Questions

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) announced its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. PLx Pharma's quarterly revenue was up 560.0% on a year-over-year basis.

When did PLx Pharma IPO?

PLx Pharma (PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What other stocks do shareholders of PLx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PLx Pharma investors own include Sorrento Therapeutics (SRNE), Ford Motor (F), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Energy Transfer (ET), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PLXP
• CUSIP: N/A
• CIK: 1497504
• Web: www.plxpharma.com
• Phone: (973) 409-6541
• Fax: 713-842-3052
• Employees: 16
• Year Founded: 2002

Profitability

• EPS (Most Recent Fiscal Year): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-46,130,000.00
• Net Margins: -606.91%
• Pretax Margin: -606.91%
• Return on Equity: -291.11%
• Return on Assets: -119.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.79
• Quick Ratio: 4.28

Sales & Book Value

• Annual Sales: $4.54 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,138,000
• Free Float: 26,530,000
• Market Cap: $603,000.00
• Optionable: Not Optionable
• Beta: 3.79